Background/Aims Gluten-free diet has an excess of fats and simple sugars and puts patients with celiac disease at risk of metabolic complications including metabolic syndrome and fatty liver. We assessed prevalence of metabolic syndrome and fatty liver in two cohorts of celiac disease.
Methods Study was done in 2 groups. In group 1, 54 treatment naïve patients with celiac disease were recruited. Of them, 44 returned after 1-year of gluten-free diet and were reassessed. In group 2, 130 celiac disease patients on gluten-free diet for ≥1 year were recruited. All patients were assessed for anthropometric and metabolic parameters and fatty liver. Metabolic syndrome was defined as per consensus definition for Asian Indians. Fatty liver was defined as controlled attenuation parameter value >263 decibels by FibroScan.
Results In group 1, of 44 treatment naïve patients with celiac disease, metabolic syndrome was present in 5 patients (11.4%) at baseline and 9 (18.2%) after 1 year of gluten-free diet. Patients having fatty liver increased from 6 patients (14.3%) at baseline to 13 (29.5%) after 1year of gluten-free diet (P=0.002). In group 2, of 130 patients with celiac disease on gluten-free diet for a median duration of 4 years, 30 out of 114 (26.3%) and 30 out of 130 patients (23%) had metabolic syndrome and fatty liver, respectively.
Conclusions Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver, which increases further with gluten-free diet. These patients should be assessed for nutritional and metabolic features and counseled about balanced diet and physical activity regularly.
Citations
Citations to this article as recorded by
Comprehensive LC-ESI-HRMS/MS Profiling and Assessment of Texture, Predicted Glycaemic Index, Antioxidant Activity and Digestive Enzyme Inhibition of Gluten- and Lactose-Free Cookies Enriched with Pomegranate By-Products Roberta Pino, Rosa Tundis, Vincenzo Sicari, Antonio Mincione, Antonio Gattuso, Chiara La Torre, Alessia Fazio, Sonia Piacente, Milena Masullo, Antonietta Cerulli, Monica Rosa Loizzo Foods.2026; 15(3): 457. CrossRef
Dietary assessments in individuals living with coeliac disease: key considerations Anne R. Lee, Melinda Dennis, Jessica Lebovits, Lori Welstead, Ritu Verma, Amelie Therrien, Benjamin Lebwohl Journal of Human Nutrition and Dietetics.2025;[Epub] CrossRef
Exploring the link between celiac disease and obesity: a potential role of gut microbiome Sunaina Addanki, Anastasia Mashukova, Arkene Levy Intestinal Research.2025; 23(2): 193. CrossRef
Raman Hyperspectroscopy and Chemometric Analysis of Blood Serum for Diagnosing Celiac Disease in Adults Entesar Al-Hetlani, Lamyaa M. Almehmadi, Igor K. Lednev Photonics.2025; 12(6): 553. CrossRef
The Gluten-Free Diet for Celiac Disease Kendra Weekley, David Gardinier, Anne R. Lee, Vanessa Weisbrod Gastrointestinal Endoscopy Clinics of North America.2025; 35(4): 753. CrossRef
Towards personalized microbial therapies for metabolic alterations in celiac disease Alejandro Borrego-Ruiz, Juan J. Borrego Exploration of Digestive Diseases.2025;[Epub] CrossRef
Effects of gluten-free diet on metabolic syndrome components and anthropometric indices in patients with nonalcoholic fatty liver disease: An open-label randomized clinical trial Maziar Jazayeri, Rasoul Zarrin, Afshin Mohammadi, Mohammad Reza Pashaei, Sajjad Ahmadpour Arab Journal of Gastroenterology.2025;[Epub] CrossRef
Hepatic Steatosis and Diet in Adult Celiac Disease: A Cross-Sectional Study Míra Zsófia Peresztegi, Zsolt Szakács, Nelli Farkas, Gábor Szekeres, Nándor Faluhelyi, Krisztina Hagymási, Gyula Pásztor, Zsófia Vereczkei, Petra Fülöp, Szilvia Lada, Sarolta Dakó, Eszter Dakó, Judit Bajor Nutrients.2025; 17(22): 3577. CrossRef
Celiac Disease as a Model of Intestinal Malnutrition: Mechanisms and Nutritional Management Vanessa Nadia Dargenio, Nicoletta Sgarro, Giovanni La Grasta, Martina Begucci, Stefania Paola Castellaneta, Costantino Dargenio, Leonardo Paulucci, Ruggiero Francavilla, Fernanda Cristofori Nutrients.2025; 17(23): 3741. CrossRef
Correlations Between Obesity and Autoimmune Diseases Anatoly I. Khavkin, Valeriya P. Novikova, Andrew V. Nalyotov, Ludmila A. Podorova, Marina Yu. Komissarova, Dmitry I. Masyuta Pediatric pharmacology.2025; 22(5): 624. CrossRef
Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet Diego Anazco, Sima Fansa, Wissam Ghusn, Khushboo Gala, Bryan Nicolalde, Elif Tama, Gerardo Calderon, Adam C. Bledsoe, Maria D. Hurtado, Joseph A. Murray, Andres Acosta Journal of Clinical Gastroenterology.2024; 58(7): 650. CrossRef
Guidelines for best practices in monitoring established coeliac disease in adult patients Luca Elli, Daniel Leffler, Christophe Cellier, Benjamin Lebwohl, Carolina Ciacci, Michael Schumann, Knut E. A. Lundin, Stefania Chetcuti Zammit, Reena Sidhu, Leda Roncoroni, Julio C. Bai, Anne R. Lee, Melinda Dennis, Marie E. Robert, Kamran Rostami, Sheri Nature Reviews Gastroenterology & Hepatology.2024; 21(3): 198. CrossRef
Probiotic Interventions in Coeliac Disease: A Systematic Review with a Focus on Cardiovascular Risk Lorretta Olu Fagbemi, Carlo Soldaini, Adele Costabile, Sofia Kolida, Carolina Ciacci, Yvonne Jeanes Gastrointestinal Disorders.2024; 6(1): 114. CrossRef
Metabolomics and lipidomics signature in celiac disease: a narrative review Mohammad Rostami-Nejad, Nastaran Asri, Sajjad Bakhtiari, Ensieh Khalkhal, Sepehr Maleki, Mostafa Rezaei-Tavirani, Somayeh Jahani-Sherafat, Kamran Rostami Clinical and Experimental Medicine.2024;[Epub] CrossRef
Coeliac disease and type 2 diabetes risk: a nationwide matched cohort and Mendelian randomisation study Shuai Yuan, Dan Leffler, Benjamin Lebwohl, Peter H. R. Green, Jiangwei Sun, Sofia Carlsson, Susanna C. Larsson, Jonas F. Ludvigsson Diabetologia.2024; 67(8): 1630. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
The Impact of a Gluten-Free Diet on Pregnant Women with Celiac Disease: Do We Need a Guideline to Manage Their Health? Yeliz Serin, Camilla Manini, Pasqualino Amato, Anil K. Verma Gastrointestinal Disorders.2024; 6(3): 675. CrossRef
The Effects of Gluten-free Diet on Body Mass Indexes in Adults with Celiac Disease Noam Peleg, Yaron Niv, Ram Dickman, Doron Boltin, Alex Krauthammer, Michal Herman-Edelstein, Nidal Issa, Jacob E. Ollech, Tom Konikoff, Rachel Gingold-Belfer Journal of Clinical Gastroenterology.2024; 58(10): 989. CrossRef
Nutrition Assessment and Management in Celiac Disease M. Ines Pinto-Sanchez, Jedid-Jah Blom, Peter R. Gibson, David Armstrong Gastroenterology.2024;[Epub] CrossRef
Celiac disease - a pluripathological model in pediatric practice Vasile Valeriu Lupu, Maria Oana Sasaran, Elena Jechel, Iuliana Magdalena Starcea, Ileana Ioniuc, Adriana Mocanu, Solange Tamara Rosu, Valentin Munteanu, Alin Horatiu Nedelcu, Ciprian Danielescu, Delia Lidia Salaru, Anton Knieling, Ancuta Lupu Frontiers in Immunology.2024;[Epub] CrossRef
Patients with Celiac Disease Have High Prevalence of Fatty Liver and Metabolic Syndrome Nishant Aggarwal, Ashish Agarwal, Hasan Alarouri, Vignesh Dwarakanathan, Sana Dang, Vineet Ahuja, Govind K. Makharia Digestive Diseases and Sciences.2024; 69(8): 3029. CrossRef
Past, Present, and Future of Noninvasive Tests to Assess Gluten Exposure, Celiac Disease Activity, and End-Organ Damage Jocelyn A. Silvester, Luca Elli, Chaitan Khosla, Jason A. Tye-Din Gastroenterology.2024; 167(1): 159. CrossRef
The Economic Iceberg of Celiac Disease: More Than the Cost of Gluten-Free Food Soran R. Bozorg, Anne R. Lee, Karl Mårild, Joseph A. Murray Gastroenterology.2024;[Epub] CrossRef
Gluten-free foods are expensive and nutritionally imbalanced than their gluten-containing counterparts Wajiha Mehtab, Samagra Agarwal, Harsh Agarwal, Anam Ahmed, Ashish Agarwal, Shubham Prasad, Ashish Chauhan, Anjali Bhola, Namrata Singh, Vineet Ahuja, Anita Malhotra, Govind K Makharia Indian Journal of Gastroenterology.2024; 43(3): 668. CrossRef
Letter: Breaking new ground—Understanding the role of ATI‐free diet in managing MASLD Matteo Spertino, Roberta Elisa Rossi, Nicola Pugliese Alimentary Pharmacology & Therapeutics.2024; 60(2): 302. CrossRef
Gluten-Free Diet—What’s Good for Celiac Disease Can Be Bad for Metabolism Kathleen Viveiros, Sonal Kumar Digestive Diseases and Sciences.2024; 69(8): 2721. CrossRef
Influence of a structured, 1-year-long dietary intervention regarding body composition and cardiovascular risk (ARCTIC) in coeliac disease: a protocol of a multicentre randomised controlled trial Zsófia Vereczkei, Zsolt Szakács, Míra Zsófia Peresztegi, Klára Lemes, Krisztina Hagymási, Sarolta Dakó, Eszter Dakó, Szilvia Lada, Nándor Faluhelyi, Gábor Szekeres, Gyula Pásztor, Nelli Farkas, Gabriella Pár, Emese Mezősi, Judit Bajor BMJ Open.2024; 14(10): e084365. CrossRef
The prevalence of obesity and underweight in celiac patients at the time of diagnosis: a systematic review and meta-analysis Farzad Maleki, Marjan Hosseinpour, Ali Delpisheh, Mansour Bahardoust, Fatemeh Hajizadeh-Sharafabad, Mohammad Reza Pashaei BMC Gastroenterology.2024;[Epub] CrossRef
Reuse of Almond Skin to Formulate a New Gluten- and Lactose-Free Bakery Product Lucia Francesca Vuono, Vincenzo Sicari, Antonio Mincione, Rosa Tundis, Roberta Pino, Natale Badalamenti, Maurizio Bruno, Francesco Sottile, Sonia Piacente, Luca Settanni, Monica Rosa Loizzo Foods.2024; 13(23): 3796. CrossRef
Celiac Disease and Liver Damage: The Gut–Liver Axis Strikes Back (Again)? A Retrospective Analysis in the Light of a Literature Review Aurelio Seidita, Federica Latteri, Mirco Pistone, Alessandra Giuliano, Luca Bertoncello, Giorgia Cavallo, Marta Chiavetta, Francesco Faraci, Alessia Nigro, Alessandro Termini, Laura Verona, Agnese Ammannato, Salvatore Accomando, Francesca Cavataio, Maria Nutrients.2024; 17(1): 85. CrossRef
Gluten: do only celiac patients benefit from its removal from the diet? Laryssa Rosa de Sousa Franckilin, Anna Clara Paiva Menezes Dos Santos, Flávio Eduardo Dias Araújo Freitas, Isabela Garbazza Vieira, Carlos Eduardo de Freitas Jorge, Daniela Godoy Neri, Maria Vitória Cota de Abreu, Janaina Koenen Fonseca, Renato Guimarães Food Reviews International.2023; 39(7): 4388. CrossRef
Risk of obesity during a gluten-free diet in pediatric and adult patients with celiac disease: a systematic review with meta-analysis Michele Barone, Andrea Iannone, Fernanda Cristofori, Vanessa Nadia Dargenio, Flavia Indrio, Elvira Verduci, Alfredo Di Leo, Ruggiero Francavilla Nutrition Reviews.2023; 81(3): 252. CrossRef
Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine Mihaela Simona Popoviciu, Nirja Kaka, Yashendra Sethi, Neil Patel, Hitesh Chopra, Simona Cavalu Journal of Personalized Medicine.2023; 13(3): 422. CrossRef
Celiac Disease and Cardiovascular Risk: A Retrospective Case-Control Study Maria Pina Dore, Sandro Mereu, Pier Sergio Saba, Michele Portoghese, Giovanni Mario Pes Journal of Clinical Medicine.2023; 12(6): 2087. CrossRef
Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease on a gluten free diet in Lebanon: a national cross-sectional study Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt F1000Research.2023; 11: 725. CrossRef
Fatty liver and celiac disease: Why worry? Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon World Journal of Hepatology.2023; 15(5): 666. CrossRef
Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease Asif Ali Hitawala, Ashraf Almomani, Somtochukwu Onwuzo, Antoine Boustany, Prabhat Kumar, Imad Asaad European Journal of Gastroenterology & Hepatology.2023; 35(9): 1030. CrossRef
Body Mass Index during Gluten-Free Diet in Patients with Celiac Disease Zsófia Vereczkei, Tímea Dergez, Zsuzsanna Fodor, Zsolt Szakács, Judit Bajor Nutrients.2023; 15(16): 3517. CrossRef
Obesity and Colorectal Cancer Jundeok Lee, Su Young Kim The Korean Journal of Gastroenterology.2023; 82(2): 63. CrossRef
Incidentally Discovered Cryptogenic Cirrhosis in a Patient with Untreated Celiac Disease Kelli Kosako Yost, Yasmin Alishahi Galician Medical Journal.2023; 30(3): E202336. CrossRef
The association of interleukin-10 single nucleotide polymorphisms (rs1800871) and serum levels in Iraqi patients with celiac disease: A case-control study Ali Hafedh Abbas, Sahar Taha Hatif, Faiq Isho Gorial, Sara Bayan Ali Clinical Epidemiology and Global Health.2023; 24: 101437. CrossRef
Unveiling the Link: A Comprehensive Narrative Review of the Relationship Between Type 1 Diabetes Mellitus and Celiac Disease Sanvi Arora, Ayush Tayade, Tanya Bhardwaj, Swanand S Pathak Cureus.2023;[Epub] CrossRef
Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis Shalimar, Anshuman Elhence, Bhavik Bansal, Hardik Gupta, Abhinav Anand, Thakur P. Singh, Amit Goel Journal of Clinical and Experimental Hepatology.2022; 12(3): 818. CrossRef
Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease in Lebanon: a national cross-sectional study Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Marwa Hallal, Michael Maitar, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt F1000Research.2022; 11: 725. CrossRef
Eating Competence and Aspects Related to a Gluten-Free Diet in Brazilian Adults with Gluten-Related Disorders Pâmela Mayara de Oliveira, Renata Puppin Zandonadi, Amanda Moreira Veloso Cutrim, Eduardo Yoshio Nakano, Fabiana Lopes Nalon de Queiroz, Raquel B. A. Botelho, Ariana Saraiva, António Raposo Nutrients.2022; 14(14): 2815. CrossRef
Nutritional status, nutrient imbalances, food-related behaviors and dietary supplements use among patients with celiac disease on a gluten free diet in Lebanon: a national cross-sectional study Maha Hoteit, Zeinab Chamas, Shaza Assaf, Malek Michael Bouhairie, Abbas Bahr, Romy Daccache, Rami Matar, Marwa Hallal, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt F1000Research.2022; 11: 725. CrossRef
Multidimensional Disadvantages of a Gluten-Free Diet in Celiac Disease: A Narrative Review Martyna Marciniak, Aleksandra Szymczak-Tomczak, Dagmara Mahadea, Piotr Eder, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak Nutrients.2021; 13(2): 643. CrossRef
The Healthy Gluten-Free Diet: Practical Tips to Prevent Metabolic Disorders and Nutritional Deficiencies in Celiac Patients Emanuele Rinninella, Marco Cintoni, Pauline Raoul, Silvia Triarico, Tommaso Dionisi, Giovanni Battista Gasbarrini, Antonio Gasbarrini, Maria Cristina Mele Gastroenterology Insights.2021; 12(2): 166. CrossRef
Nutritional Properties of Rice Varieties Commonly Consumed in Italy and Applicability in Gluten Free Diet Giorgia Vici, Diego Romano Perinelli, Dalia Camilletti, Flora Carotenuto, Luca Belli, Valeria Polzonetti Foods.2021; 10(6): 1375. CrossRef
Physical development in children with celiac disease in St. Petersburg N. S. Shapovalova, V. P. Novikova, K. A. Klikunova Experimental and Clinical Gastroenterology.2021; (4): 116. CrossRef
Celiac disease and obesity: the possibility of comboridity of pathology in children V. P. Novikova, V. L. Gritsinskaya, A. I. Khavkin Experimental and Clinical Gastroenterology.2021; (4): 124. CrossRef
Background/Aims The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.
Methods This retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated).
Results Of 69 patients (22 ulcerative colitis/47 Crohn’s disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5–48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0–84.5 weeks) of IFX. Of these 8 patients’ none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn’s disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation.
Conclusions There is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX.
Citations
Citations to this article as recorded by
ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena Journal of Crohn’s and Colitis.2026;[Epub] CrossRef
Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study Daya Krishna Jha, Shilpa Prasad, Arun Valsan, Shubhra Mishra, Priya Nair, Anoop K Koshy, Sonal Singh, Ajay Shankar Prasad, Rajat Shukla, Rizwan Ahamed, Philip Augustine, Kartik Natarajan, Kiran Peddi, Akshay Kulkarni, Sumit Bhatia, Aditya V Pachisia, Prad World Journal of Gastroenterology.2026;[Epub] CrossRef
Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale Arab Journal of Gastroenterology.2025; 26(1): 33. CrossRef
Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review Daya Krishna Jha, Rinkalben Kakadiya, Ananya Sharma, Shankar Naidu, Dipankar De, Vishal Sharma Autoimmunity Reviews.2025; 24(3): 103758. CrossRef
Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: is the risk still too great? A case report Miguel Ángel Moyón, Johan Stephany Añazco, Alex Enrique Vásconez, David Larreategui, María Belén Torres, Natali Moyón, Tatiana Borja, Gabriel Alejandro Molina Journal of Surgical Case Reports.2025;[Epub] CrossRef
Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future Manish Manrai, Atul Abhishek Jha, Saurabh Dawra, Aditya Vikram Pachisia Future Pharmacology.2024; 4(1): 279. CrossRef
RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS Didia B CURY, Liana C B CURY, Ana C MICHELETTI, Rogério A OLIVEIRA, José J S GONÇALVES Arquivos de Gastroenterologia.2024;[Epub] CrossRef
(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange Clinical Microbiology and Infection.2024; 30(8): 989. CrossRef
“Mitigating tuberculosis reactivation risk in IBD patients on anti-TNF therapy” Peeyush Kumar, Saurabh Kedia, Vineet Ahuja Arab Journal of Gastroenterology.2024; 25(4): 455. CrossRef
Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review Nina Jahnich, Peter D. Arkwright Frontiers in Pharmacology.2023;[Epub] CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park Clinical Endoscopy.2023; 56(2): 239. CrossRef
CT in the detection of latent tuberculosis: a systematic review N. Moore, M. Maher, G. Murphy, M. O'Callaghan Maher, O.J. O'Connor, M.F. McEntee Clinical Radiology.2023; 78(8): 568. CrossRef
Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood ACG Case Reports Journal.2023; 10(6): e01066. CrossRef
The Risk of Opportunistic Infections in Patients with Inflammatory
Bowel Disease Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari The International Journal of Gastroenterology and Hepatology Diseases.2022;[Epub] CrossRef
Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017 Shereen S Katrak, Rongxia Li, Sue Reynolds, Suzanne M Marks, Jessica R Probst, Terence Chorba, Kevin Winthrop, Kenneth G Castro, Neela D Goswami Open Forum Infectious Diseases.2022;[Epub] CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Increased Risk of Infection With High Infliximab Trough Level Suprabhat Giri, Harish Darak Journal of Clinical Gastroenterology.2022; 56(4): 374. CrossRef
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply Peeyush Kumar, Sudheer Kumar Vuyyuru, Saurabh Kedia, Vineet Ahuja Alimentary Pharmacology & Therapeutics.2022; 55(10): 1348. CrossRef
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef
Tumor necrosis factor-alpha antibody labeled-polyethylene glycol-coated nanoparticles: A mesenchymal stem cells-based drug delivery system in the rat model of cisplatin-induced nephrotoxicity Faten A. M. Abo-Aziza, Saleh M. Albarrak, Abdel-Kader A. Zaki, Shaymaa E. El-Shafey Veterinary World.2022; : 2475. CrossRef
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Saurabh Kedia, Pabitra Sahu, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Kumar, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Govind Makharia, Vineet Ahuja Indian Journal of Gastroenterology.2022; 41(5): 446. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents Adam Krusiński, Anna Grzywa-Celińska, Katarzyna Szewczyk, Luiza Grzycka-Kowalczyk, Justyna Emeryk-Maksymiuk, Janusz Milanowski, Andrew S. Day International Journal of Inflammation.2021; 2021: 1. CrossRef
Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease Sudheer K Vuyyuru, Devendra Desai, Saurabh Kedia, Pavan Dhoble, Pabitra Sahu, Bhaskar Kante, Samagra Agarwal, Sawan Bopanna, Rajan Dhingra, Pratap Mouli Venigalla, Raju Sharma, Siddhartha Datta Gupta, Govind Makharia, Peush Sahni, Vineet Ahuja JGH Open.2021; 5(4): 420. CrossRef
Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang Journal of Digestive Diseases.2021; 22(8): 473. CrossRef
COVID-19-associated opportunistic infections: a snapshot on the current reports Amir Abdoli, Shahab Falahi, Azra Kenarkoohi Clinical and Experimental Medicine.2021; 22(3): 327. CrossRef
Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis Sudheer K Vuyyuru, Saurabh Kedia, Mani Kalaivani, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh K Ranjan, Govind Makharia, Ashwin Ananthakrishnan, Vineet Ahuja Future Microbiology.2021; 16(15): 1215. CrossRef
A case report of probable ocular tuberculosis following biologics Sudha K. Ganesh, Divya Thatikonda Indian Journal of Ophthalmology - Case Reports.2021; 1(4): 683. CrossRef
Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park BMC Gastroenterology.2021;[Epub] CrossRef
Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri Indian Journal of Gastroenterology.2021; 40(6): 598. CrossRef
Vedolizumab in Inflammatory Bowel Disease: West versus East Prasanta Debnath, Pravin M. Rathi Inflammatory Intestinal Diseases.2021; 6(1): 1. CrossRef
Antitubercular Therapy Given to Differentiate Crohn’s Disease From Intestinal Tuberculosis Predisposes to Stricture Formation Akshita Gupta, Venigalla Pratap Mouli, Srikant Mohta, Bhaskar Kante, Mani Kalaivani, Deepak Madhu, Pabitra Sahu, Sudheer Kumar, Raju Sharma, Peush Sahni, Prasenjit Das, Siddharth Datta Gupta, Govind Makharia, Saurabh Kedia, Vineet Ahuja Journal of Crohn's and Colitis.2020; 14(11): 1611. CrossRef
Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja Indian Journal of Gastroenterology.2020; 39(4): 388. CrossRef
Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model Jung Min Kim, Da Hye Kim, Hyo Jeong Park, Hyun Woo Ma, I Seul Park, Mijeong Son, So Youn Ro, Seokmann Hong, Hyo Kyung Han, Soo Jeong Lim, Seung Won Kim, Jae Hee Cheon Journal of Nanobiotechnology.2020;[Epub] CrossRef
Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: A cohort analysis Sudheer K. Vuyyuru, Pabitra Sahu, Saurabh Kedia, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Raju Sharma, Govind Makharia, S. D. Gupta, Peush Sahni, Vineet Ahuja Indian Journal of Gastroenterology.2020; 39(5): 435. CrossRef
Higher risk of tuberculosis in combination therapy for inflammatory bowel disease Seong Ji Choi, Min Sun Kim, Eun Sun Kim, Juneyoung Lee, Jae Min Lee, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim Medicine.2020; 99(44): e22897. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim The Korean Journal of Gastroenterology.2019; 74(3): 168. CrossRef